We are thus convinced that the findings described herein will not only guide the design and the development of next-generation inhibitors to overcome toxicity-associated brain permeability and the current landscape of resistance mutations in GIST but will also have an impact on other cancers where mutated receptor tyrosine kinases are oncogenic drivers. This evidence concerns the gene NTRK1 and cancer.